Cartesian Therapeutics

Cartesian Therapeutics Tangible Book Value per Share

The Tangible Book Value per Share of Cartesian Therapeutics (RNAC) as of Nov 17, 2026 is -6.71 USD. In the previous year, Tangible Book Value per Share was -7.91 USD — a change of -15.16% (higher).

Tangible Book Value per Share

-6.71USD

YoY

-15.16%

Last updated:

Tangible Book Value per Share of Cartesian Therapeutics is 2025 -6.71 USD. Tangible Book Value per Share of Cartesian Therapeutics was 2024 -7.91 USD. It decreases by -15.16% higher compared to the previous year.

The Cartesian Therapeutics Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
-0.21 USD
Jan 1, 2019
0.32 USD
Jan 1, 2020
-0.69 USD
Jan 1, 2021
0.87 USD
Jan 1, 2022
3.61 USD
Jan 1, 2023
-24.57 USD
Jan 1, 2024
-7.91 USD
Jan 1, 2025
-6.71 USD
The Cartesian Therapeutics Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
-6.71USD-15.16%
-7.91USD-67.83%
-24.57USD-780.98%
3.61USD+316.62%
0.87USD-225.07%
-0.69USD-314.43%
0.32USD-254.98%
-0.21USD-110.46%
1.99USD-5.72%
2.11USD-147.18%
-4.48USD+32.75%
-3.38USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cartesian Therapeutics Stock analysis

What does Cartesian Therapeutics do? Selecta Biosciences develops Descartes-08, an RNA-engineered chimeric antigen receptor T-cell therapy in Phase IIb trials for generalized myasthenia gravis, an autoimmune disorder causing muscle weakness. The company leverages its RNA Armory platform to optimize engineered cells for diverse cell therapies, including autologous and allogeneic approaches. Descartes-08 holds Orphan Drug Designation from the FDA for myasthenia gravis treatment. Clinical-stage biopharmaceutical companies like Selecta typically generate revenue through partnerships with pharmaceutical firms for drug development and licensing agreements, though specific partnerships are not detailed in the description. The company focuses on autoimmune diseases, particularly myasthenia gravis, with Descartes-08 as its lead asset. Its technology platform enables precision control of engineered cells, supporting cell therapy modalities. Selecta’s business model relies on advancing clinical-stage therapies toward regulatory approval and commercialization, with potential revenue streams from clinical trial partnerships and future product sales. Selecta Biosciences operates as a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, with Descartes-08 as its primary asset in Phase IIb development. The company’s revenue model centers on developing therapies for rare diseases, utilizing Orphan Drug Designation to facilitate regulatory pathways and potential market exclusivity. While the description does not specify exact revenue sources, the focus on clinical development and FDA designations suggests reliance on biopharmaceutical partnerships and licensing deals. Cartesian Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cartesian Therapeutics stock

Tangible Book Value per Share of Cartesian Therapeutics is -6.71 USD in 2025.

Tangible Book Value per Share of Cartesian Therapeutics changed from -7.91 USD to -6.71 USD, representing a -15.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Cartesian Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cartesian Therapeutics

All Key Metrics — Cartesian Therapeutics